HEAL Stock Price | iShares Healthcare Innovation UCITS ETF USD (Acc) P/E, Revenue, EPS, & Forecasts

iShares Healthcare Innovation UCITS ETF USD (Acc) • HEAL

HEAL current price

$7.86+18.37%

Capital at risk.

About
Metrics
Sector breakdown
Regional breakdown
Top 10 Holdings
FAQs
News

-0.63%

-0.88%

+1.42%

+6.79%

+18.37%

MAX

+59.76%

About iShares Healthcare Innovation UCITS ETF USD (Acc)

Base currency

$ USD

Trading Cyrrency

USD

ISIN

IE00BYZK4776

Trading on

LSE

Ticker

HEAL

Fund manager

iShares

Key facts & metrics

BasicAdvanced

Fund size

$1.13B

income

Distributing

Expense Ratio

40.00%

Dividend Yield

0.92319

Valuation

Price to prospective earnings

20.99

Price to book

3.89

Price to sales

3.67

Price to cashflow

16.97

Price

52-week High

$8.20

52-week Low

$6.05

50-day moving average

$7.92

200-day moving average

$7.59

Technicals

YTD

2.73%

Year 1

10.40%

Year 3

5.37%

Year 5

5.67%

Year 10

0.00%

Volatility Year 1

20.70%

Volatility Year 3

15.83%

Expected Return Year 3

5.70%

Sharpe Ratio

0.58%

Growth

Long term projected earnings

12.11%

Historical earnings

4.79%

Sales

0.05%

Cash flow

14.54%

Book value

5.43%

Sector breakdown

Healthcare

% 98,49

Technology

% 1,51

Regional breakdown

North America

% 70,14

Europe

% 15,82

Asia

% 12,49

% 1,55

Top 10 Holdings

Argen-X

1.94%

UCB SA

1.82%

Gilead Sciences

1.73%

Roche

1.7%

Lonza Group AG

1.69%

AbbVie

1.67%

Intuitive Surgical Inc

1.66%

IQVIA Holdings

1.66%

Illumina

1.65%

Bristol-Myers Squibb

1.65%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

What is the name of HEAL?

The name of HEAL is iShares Healthcare Innovation UCITS ETF USD (Acc).

What is the ticker of iShares Healthcare Innovation UCITS ETF USD (Acc)?

The primary ticker of iShares Healthcare Innovation UCITS ETF USD (Acc) is HEAL.

What is the ISIN of iShares Healthcare Innovation UCITS ETF USD (Acc)?

The ISIN of iShares Healthcare Innovation UCITS ETF USD (Acc) is IE00BYZK4776.

What are the costs of iShares Healthcare Innovation UCITS ETF USD (Acc)

The total expense ratio (TER) of iShares Healthcare Innovation UCITS ETF USD (Acc) amounts to 40.00% p.a. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately.

Does iShares Healthcare Innovation UCITS ETF USD (Acc) pay dividends?

Yes, iShares Healthcare Innovation UCITS ETF USD (Acc) does pay dividends.

What currency is iShares Healthcare Innovation UCITS ETF USD (Acc) traded in?

iShares Healthcare Innovation UCITS ETF USD (Acc) is traded in USD.

Is iShares Healthcare Innovation UCITS ETF USD (Acc) an accumulating or distributing ETF?

iShares Healthcare Innovation UCITS ETF USD (Acc) is distributing.

Who is the fund manager of “iShares Healthcare Innovation UCITS ETF USD (Acc)?

The fund manager of iShares Healthcare Innovation UCITS ETF USD (Acc) is iShares.

What is the fund size of iShares Healthcare Innovation UCITS ETF USD (Acc)?

The fund size of iShares Healthcare Innovation UCITS ETF USD (Acc) is $1.13B.

iShares Healthcare Innovation UCITS ETF USD (Acc) news

thumb_up_alt

•Positive

Here's Why Novartis (NVS) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research•13h ago

thumb_down_alt

•Negative

Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research•13h ago

thumbs_up_down

•Neutral

Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research•13h ago

Invest your money to its potential

When you invest your capital is at risk.